What's Happening?
TTP Group has announced the sale of LEX Diagnostics Limited to QuidelOrtho Corporation, a leader in in vitro diagnostics. LEX Diagnostics, a UK-based company, was founded in 2020 as a spin-out from TTP Group.
It developed a point-of-care molecular testing platform capable of delivering PCR results in minutes, utilizing a breakthrough in ultra-fast thermal control. The VELO system, a product of LEX Diagnostics, received U.S. FDA 510(k) clearance and CLIA waived status in February 2026, allowing it to provide lab-quality results for Flu A, Flu B, and COVID-19 directly from a swab sample. This acquisition is seen as a significant step in bringing high-quality molecular PCR testing closer to patients, facilitating faster diagnosis and clinical decisions.
Why It's Important?
The acquisition of LEX Diagnostics by QuidelOrtho is significant for the healthcare industry, particularly in the U.S., as it promises to enhance the accessibility and speed of molecular testing. The VELO system's ability to deliver rapid and accurate results can improve patient care by enabling quicker diagnosis and treatment decisions. This development is crucial in the context of ongoing public health challenges, such as flu and COVID-19, where timely diagnosis can significantly impact patient outcomes. The acquisition also highlights the potential for innovative technologies to transition from concept to market, demonstrating the value of strategic partnerships in the healthcare sector.
What's Next?
Following the acquisition, QuidelOrtho is expected to integrate LEX Diagnostics' technology into its existing portfolio, potentially expanding the reach and application of the VELO system. This could lead to broader adoption in various healthcare settings, including urgent care centers and pharmacies. The focus will likely be on scaling the technology to meet the demands of the U.S. market, enhancing the company's competitive edge in the diagnostics industry. Stakeholders, including healthcare providers and patients, may anticipate improved access to rapid testing solutions, which could influence future healthcare delivery models.
